IN8bio

IN8bio is a clinical-stage biotechnology company developing gamma-delta T-cell therapies and gamma-delta T-cell engagers for oncology and autoimmune indications. Its pipeline includes genetically modified autologous therapies for glioblastoma and an allogeneic therapy for high-risk leukemia; the company has not yet commercialized a product or generated product revenue.

Relationship details are part of the Pro plan.